Journal of Arthritis

ISSN - 2167-7921

Rituparna Bhattacharya

Rituparna Bhattacharya
School of Pharmacy,
Morgantown, West Virginia

  • Research Article
    Budget Impact Analysis of Tofacitinib for treatment of Rheumatoid Arthritis
    Author(s): Rituparna Bhattacharya and Khalid M. KamalRituparna Bhattacharya and Khalid M. Kamal

    Objective: Tofacitinib is a novel oral biologic that has been approved for treating adults with Rheumatoid arthritis (RA) having inadequate response to or are intolerant of methotrexate (MTX). The objective of this study was to conduct a budget impact model (BIM) analysis for estimating direct annual drug costs for individuals with RA before and after the introduction tofacitinib as a formulary option. Research Design and Methods: The BIM was developed using a US healthcare payer?s perspective with a one-year time frame. The tumor necrosis factor inhibitors (anti-TNFs) adalimumab, etanercept, infliximab, golimumab and certolizumab were considered as comparators. The BIM tested two base-case scenarios: ?Base-case scenario 1: Incident anti-TNF users?; ?Base-case scenario 2: Prevalent anti-TNF users?. Both the scenarios were evaluated under the following two conditions: (1) assuming mono.. View More»

    DOI: 10.4172/2167-7921.1000152

    Abstract PDF

Relevant Topics